Siteman Investment Program Research Development Awards (SIP RDAs)

The SIP RDA will fund research projects twice per year. Currently, there are six mechanisms available:

  • CLINICAL TRIAL CATEGORY
    • New Clinical Trial Mechanism; up to $300,000 over 3 years
    • Existing Clinical Trial Mechanism; up to $200,000 over 2 years
  • PRE-R01 CATEGORY
    • The Pedal the Cause Pre-R01 Mechanism; up to $200,000 over 2 years
    • Pre-R01 Mechanism with a Cancer Prevention & Control Emphasis; up to $200,000 over 2 years
    • Pre-R01 Mechanism for University of Missouri-Columbia Collaboration; up to $200,000 over 2 years
  • TEAM SCIENCE CATEGORY
    • Team Science Mechanism; up to $800,000 over 2 years

Complete information on each mechanism can be found in the Request for Applications (RFA) each cycle. A RFA will be announced twice per year on the following schedule:

GENERAL SIP DATE GUIDELINES* Cycle 1 Cycle 2
Announcement: January 15 July 15
Statement of Intent deadline: March 1 September 1
Full applications due: April 1 October 1
Anticipated decision notices: June 15 December 15
Start dates: July 1 January 1
*Dates may vary based on weekends, holidays, and other unforeseen circumstances.

Please consult the specific cycle’s RFA announcement for official deadlines.

2021 Cycle 2 Official Dates
Announcement: July 15, 2021
Statement of Intent Submission deadline: September 1, 2021
Application deadline: October 1, 2021
Anticipated decision notice: December 15, 2021
Start date: January 1, 2022

2021 Cycle 2 Application Documents

SIP RDA Request for Applications (RFA)
SIP RDA Application Cover Sheet – PDF Version *preferred* (required – updated 07/2021)
SIP RDA Application Cover Sheet – Word Version (required – updated 07/2021)
SIP RDA Clinical Trial Category Budget Form (required – updated 07/2020)

Success Rates

Success rates have been computed over the span of SIP RDA by mechanism and include applications that were scientifically reviewed. Success rates are determined by dividing the number of applications funded by the total number of applications reviewed. The current success rate for the Pre-R01 Category is 22%.

Re-submissions are welcome and encouraged every cycle. The success rate for re-submissions across all mechanisms is 37%.

Previous Awardees

Contact Jaclyn McGuire at Siteman Cancer Center for more information, mcguirej@wustl.edu.